| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 93 | 2024 | 882 | 12.360 |
Why?
|
| Kidney Failure, Chronic | 18 | 2022 | 432 | 2.630 |
Why?
|
| Pregnancy Complications | 11 | 2021 | 356 | 2.540 |
Why?
|
| Nephrology | 9 | 2024 | 46 | 2.470 |
Why?
|
| Immunosuppressive Agents | 29 | 2019 | 995 | 2.270 |
Why?
|
| Pregnancy Outcome | 10 | 2021 | 273 | 2.070 |
Why?
|
| Graft Rejection | 32 | 2021 | 1128 | 1.980 |
Why?
|
| Kidney Diseases | 13 | 2024 | 325 | 1.960 |
Why?
|
| Polyomavirus Infections | 10 | 2024 | 29 | 1.920 |
Why?
|
| BK Virus | 8 | 2024 | 24 | 1.630 |
Why?
|
| Living Donors | 15 | 2019 | 348 | 1.580 |
Why?
|
| Tumor Virus Infections | 8 | 2024 | 83 | 1.400 |
Why?
|
| Pre-Eclampsia | 4 | 2023 | 268 | 1.210 |
Why?
|
| Isoxazoles | 5 | 2011 | 78 | 1.100 |
Why?
|
| Kidney | 16 | 2023 | 1156 | 1.040 |
Why?
|
| Renal Dialysis | 9 | 2023 | 363 | 0.900 |
Why?
|
| Nephrology Nursing | 1 | 2024 | 1 | 0.880 |
Why?
|
| Antiviral Agents | 6 | 2024 | 506 | 0.850 |
Why?
|
| Humans | 135 | 2024 | 95971 | 0.840 |
Why?
|
| Pregnancy | 15 | 2023 | 3241 | 0.820 |
Why?
|
| Organ Transplantation | 5 | 2024 | 298 | 0.770 |
Why?
|
| Graft Survival | 12 | 2021 | 943 | 0.740 |
Why?
|
| Contraception | 2 | 2021 | 101 | 0.720 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2018 | 258 | 0.720 |
Why?
|
| Tissue Donors | 5 | 2021 | 542 | 0.690 |
Why?
|
| Critical Pathways | 1 | 2021 | 36 | 0.670 |
Why?
|
| Capparis | 1 | 2020 | 1 | 0.660 |
Why?
|
| Cardiovascular System | 1 | 2020 | 64 | 0.620 |
Why?
|
| Pancreas Transplantation | 8 | 2004 | 105 | 0.600 |
Why?
|
| Tacrolimus | 12 | 2019 | 373 | 0.590 |
Why?
|
| Female | 66 | 2024 | 49938 | 0.560 |
Why?
|
| Hypertension | 5 | 2017 | 776 | 0.560 |
Why?
|
| Risk Factors | 17 | 2023 | 5949 | 0.550 |
Why?
|
| Fertility | 3 | 2013 | 119 | 0.540 |
Why?
|
| Viremia | 1 | 2017 | 53 | 0.520 |
Why?
|
| Computers, Handheld | 2 | 2016 | 34 | 0.510 |
Why?
|
| Career Mobility | 1 | 2017 | 43 | 0.510 |
Why?
|
| Midodrine | 1 | 2016 | 5 | 0.500 |
Why?
|
| Postoperative Complications | 11 | 2021 | 2540 | 0.500 |
Why?
|
| Sexism | 1 | 2017 | 57 | 0.490 |
Why?
|
| Anemia | 3 | 2015 | 137 | 0.490 |
Why?
|
| DNA, Viral | 1 | 2017 | 274 | 0.490 |
Why?
|
| Kidney Function Tests | 2 | 2018 | 119 | 0.490 |
Why?
|
| Vasoconstrictor Agents | 1 | 2016 | 68 | 0.480 |
Why?
|
| Mentors | 1 | 2017 | 99 | 0.480 |
Why?
|
| Allografts | 5 | 2023 | 205 | 0.470 |
Why?
|
| Attitude to Health | 6 | 2018 | 227 | 0.460 |
Why?
|
| Parvoviridae Infections | 1 | 2015 | 6 | 0.460 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2015 | 13 | 0.460 |
Why?
|
| Leadership | 1 | 2017 | 158 | 0.450 |
Why?
|
| Nephritis, Interstitial | 5 | 2005 | 44 | 0.450 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2016 | 126 | 0.440 |
Why?
|
| Choice Behavior | 1 | 2016 | 165 | 0.440 |
Why?
|
| Transplant Recipients | 3 | 2021 | 157 | 0.440 |
Why?
|
| Mobile Applications | 1 | 2016 | 81 | 0.440 |
Why?
|
| Renal Insufficiency | 3 | 2016 | 99 | 0.440 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 185 | 0.430 |
Why?
|
| Donor Selection | 2 | 2018 | 81 | 0.420 |
Why?
|
| Middle Aged | 52 | 2024 | 28255 | 0.400 |
Why?
|
| Tissue and Organ Procurement | 6 | 2023 | 388 | 0.390 |
Why?
|
| Influenza Vaccines | 2 | 2014 | 173 | 0.390 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2010 | 649 | 0.390 |
Why?
|
| United States | 15 | 2024 | 7762 | 0.380 |
Why?
|
| Patient Selection | 2 | 2016 | 708 | 0.370 |
Why?
|
| Creatinine | 11 | 2017 | 299 | 0.370 |
Why?
|
| Male | 61 | 2024 | 45735 | 0.370 |
Why?
|
| Fractures, Bone | 3 | 2008 | 155 | 0.370 |
Why?
|
| Cyclosporine | 7 | 2004 | 242 | 0.370 |
Why?
|
| Infant, Newborn | 4 | 2023 | 2612 | 0.350 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2015 | 570 | 0.350 |
Why?
|
| Adult | 49 | 2024 | 28637 | 0.340 |
Why?
|
| Pregnancy, High-Risk | 1 | 2011 | 16 | 0.340 |
Why?
|
| Long-Term Care | 1 | 2011 | 63 | 0.340 |
Why?
|
| Nephrectomy | 7 | 2022 | 297 | 0.340 |
Why?
|
| Time Factors | 15 | 2019 | 5577 | 0.320 |
Why?
|
| Survivors | 1 | 2011 | 204 | 0.320 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2012 | 37 | 0.310 |
Why?
|
| Polyomavirus | 2 | 2006 | 16 | 0.310 |
Why?
|
| Nephritis | 3 | 2018 | 18 | 0.300 |
Why?
|
| Bone Diseases | 3 | 2008 | 54 | 0.290 |
Why?
|
| Endpoint Determination | 2 | 2018 | 58 | 0.290 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2019 | 284 | 0.280 |
Why?
|
| Transplantation, Homologous | 14 | 2023 | 1022 | 0.280 |
Why?
|
| Antilymphocyte Serum | 4 | 2006 | 69 | 0.280 |
Why?
|
| Surveys and Questionnaires | 12 | 2019 | 2863 | 0.280 |
Why?
|
| Kidney Calculi | 2 | 2009 | 345 | 0.280 |
Why?
|
| Reproduction | 2 | 2006 | 203 | 0.280 |
Why?
|
| Activities of Daily Living | 2 | 2019 | 215 | 0.280 |
Why?
|
| Treatment Outcome | 17 | 2024 | 9092 | 0.270 |
Why?
|
| Health Status | 4 | 2019 | 386 | 0.270 |
Why?
|
| Premature Birth | 3 | 2018 | 130 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 4 | 2018 | 1096 | 0.270 |
Why?
|
| Immunocompromised Host | 2 | 2007 | 147 | 0.260 |
Why?
|
| Vitamin D Deficiency | 1 | 2008 | 107 | 0.260 |
Why?
|
| Influenza, Human | 1 | 2010 | 370 | 0.260 |
Why?
|
| Islets of Langerhans Transplantation | 3 | 2021 | 247 | 0.250 |
Why?
|
| Smoking | 1 | 2010 | 650 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 937 | 0.240 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 683 | 0.230 |
Why?
|
| Biopsy | 11 | 2018 | 1221 | 0.230 |
Why?
|
| Public Opinion | 3 | 2015 | 51 | 0.230 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 564 | 0.220 |
Why?
|
| Calcium Channel Agonists | 1 | 2004 | 13 | 0.220 |
Why?
|
| Research Design | 2 | 2018 | 631 | 0.220 |
Why?
|
| Societies, Nursing | 1 | 2024 | 2 | 0.220 |
Why?
|
| Hemodynamics | 6 | 1990 | 780 | 0.220 |
Why?
|
| Azathioprine | 3 | 2004 | 125 | 0.220 |
Why?
|
| Calcifediol | 1 | 2004 | 22 | 0.210 |
Why?
|
| Breast Feeding | 3 | 2011 | 108 | 0.210 |
Why?
|
| Calcitriol | 1 | 2004 | 173 | 0.210 |
Why?
|
| Aged | 28 | 2024 | 20877 | 0.210 |
Why?
|
| Quality of Life | 5 | 2019 | 1817 | 0.200 |
Why?
|
| Clinical Trials as Topic | 4 | 2017 | 1178 | 0.200 |
Why?
|
| Acute Disease | 5 | 2013 | 871 | 0.200 |
Why?
|
| Health Promotion | 1 | 2024 | 176 | 0.190 |
Why?
|
| Glomerular Filtration Rate | 3 | 2024 | 289 | 0.190 |
Why?
|
| Papillomavirus Infections | 1 | 2006 | 301 | 0.190 |
Why?
|
| Complement C4b | 3 | 2013 | 33 | 0.180 |
Why?
|
| Internet | 2 | 2015 | 339 | 0.180 |
Why?
|
| Family | 3 | 2014 | 333 | 0.180 |
Why?
|
| Antihypertensive Agents | 2 | 2017 | 265 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 2 | 2006 | 1430 | 0.180 |
Why?
|
| Consensus | 3 | 2019 | 370 | 0.180 |
Why?
|
| Coronary Disease | 7 | 1988 | 263 | 0.180 |
Why?
|
| Diabetes Mellitus | 3 | 2004 | 771 | 0.180 |
Why?
|
| Health Services Accessibility | 2 | 2017 | 490 | 0.170 |
Why?
|
| Total Quality Management | 1 | 2000 | 34 | 0.170 |
Why?
|
| Frailty | 1 | 2022 | 94 | 0.170 |
Why?
|
| Organophosphonates | 3 | 2024 | 53 | 0.160 |
Why?
|
| Hospitals, University | 3 | 2012 | 198 | 0.160 |
Why?
|
| Waiting Lists | 4 | 2018 | 212 | 0.160 |
Why?
|
| B-Lymphocytes | 3 | 2021 | 773 | 0.160 |
Why?
|
| Life Style | 2 | 2019 | 186 | 0.160 |
Why?
|
| Delphi Technique | 2 | 2017 | 136 | 0.160 |
Why?
|
| Glomerulonephritis, Membranous | 2 | 2003 | 23 | 0.160 |
Why?
|
| Peptide Fragments | 3 | 2013 | 477 | 0.160 |
Why?
|
| Biological Variation, Individual | 1 | 2019 | 7 | 0.160 |
Why?
|
| Work Capacity Evaluation | 1 | 2019 | 5 | 0.160 |
Why?
|
| Calcium | 1 | 2004 | 1205 | 0.160 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1999 | 18 | 0.160 |
Why?
|
| Drug Therapy, Combination | 6 | 2006 | 816 | 0.160 |
Why?
|
| Sick Leave | 1 | 2019 | 15 | 0.160 |
Why?
|
| Cytosine | 3 | 2024 | 135 | 0.160 |
Why?
|
| Nephrolithiasis | 1 | 2019 | 25 | 0.150 |
Why?
|
| Infection Control | 1 | 2021 | 132 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 930 | 0.150 |
Why?
|
| Mental Health | 3 | 2019 | 202 | 0.150 |
Why?
|
| Blood Pressure | 5 | 2016 | 929 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 139 | 0.150 |
Why?
|
| Multiple Organ Failure | 1 | 2019 | 60 | 0.150 |
Why?
|
| Sex Factors | 3 | 2018 | 1132 | 0.150 |
Why?
|
| Retrospective Studies | 10 | 2024 | 10190 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2019 | 120 | 0.150 |
Why?
|
| Biological Products | 1 | 2021 | 179 | 0.140 |
Why?
|
| Bowman Capsule | 1 | 2018 | 6 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 297 | 0.140 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 1998 | 5 | 0.140 |
Why?
|
| Proteinuria | 1 | 2018 | 70 | 0.140 |
Why?
|
| Education | 1 | 2018 | 60 | 0.140 |
Why?
|
| Hospitals, Community | 1 | 1998 | 34 | 0.140 |
Why?
|
| Heart Failure | 3 | 2019 | 1424 | 0.140 |
Why?
|
| Health Care Surveys | 2 | 2010 | 296 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2021 | 817 | 0.130 |
Why?
|
| Plasma | 1 | 2017 | 51 | 0.130 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2017 | 48 | 0.130 |
Why?
|
| Counseling | 2 | 2011 | 175 | 0.130 |
Why?
|
| Telemedicine | 1 | 2021 | 230 | 0.130 |
Why?
|
| Plasma Cells | 2 | 2012 | 88 | 0.130 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 191 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 342 | 0.130 |
Why?
|
| Steroids | 1 | 1998 | 173 | 0.130 |
Why?
|
| Cadaver | 5 | 2007 | 201 | 0.130 |
Why?
|
| Fatigue | 1 | 2018 | 185 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2021 | 595 | 0.130 |
Why?
|
| Directive Counseling | 1 | 2017 | 35 | 0.130 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2018 | 85 | 0.130 |
Why?
|
| Income | 1 | 2017 | 89 | 0.130 |
Why?
|
| Hepatitis C | 1 | 2018 | 185 | 0.130 |
Why?
|
| Personal Autonomy | 2 | 2014 | 120 | 0.130 |
Why?
|
| Immunohistochemistry | 3 | 2017 | 1829 | 0.130 |
Why?
|
| Crotonates | 2 | 2006 | 12 | 0.120 |
Why?
|
| Toluidines | 2 | 2006 | 18 | 0.120 |
Why?
|
| Minority Groups | 1 | 2017 | 155 | 0.120 |
Why?
|
| Motivation | 2 | 2015 | 310 | 0.120 |
Why?
|
| Hydroxybutyrates | 2 | 2006 | 27 | 0.120 |
Why?
|
| Caregivers | 1 | 2017 | 186 | 0.120 |
Why?
|
| Parvovirus B19, Human | 1 | 2015 | 3 | 0.120 |
Why?
|
| Self Report | 2 | 2019 | 328 | 0.120 |
Why?
|
| Hypertension, Renal | 1 | 2015 | 19 | 0.120 |
Why?
|
| Inflammation | 1 | 2021 | 1069 | 0.110 |
Why?
|
| Aniline Compounds | 2 | 2006 | 63 | 0.110 |
Why?
|
| Nitriles | 2 | 2006 | 157 | 0.110 |
Why?
|
| Health Personnel | 1 | 2017 | 241 | 0.110 |
Why?
|
| Capillaries | 3 | 2005 | 86 | 0.110 |
Why?
|
| Parathyroid Hormone | 2 | 2008 | 226 | 0.110 |
Why?
|
| Compensation and Redress | 1 | 2015 | 27 | 0.110 |
Why?
|
| Calcineurin Inhibitors | 1 | 2015 | 53 | 0.110 |
Why?
|
| Pleural Effusion | 1 | 1995 | 46 | 0.110 |
Why?
|
| Pleura | 1 | 1995 | 32 | 0.110 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2015 | 60 | 0.110 |
Why?
|
| Bupivacaine | 1 | 1995 | 48 | 0.110 |
Why?
|
| Liver Transplantation | 2 | 2019 | 1201 | 0.110 |
Why?
|
| Adolescent | 9 | 2017 | 9888 | 0.110 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 1994 | 201 | 0.110 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 174 | 0.110 |
Why?
|
| Analgesia | 1 | 1995 | 63 | 0.110 |
Why?
|
| Self Care | 1 | 2015 | 171 | 0.110 |
Why?
|
| Focus Groups | 1 | 2015 | 191 | 0.110 |
Why?
|
| T-Lymphocytes | 3 | 2018 | 1317 | 0.110 |
Why?
|
| Vitamin D | 2 | 2008 | 273 | 0.110 |
Why?
|
| Telenursing | 1 | 2013 | 2 | 0.110 |
Why?
|
| Culture | 1 | 2014 | 54 | 0.110 |
Why?
|
| Obesity | 1 | 2021 | 1038 | 0.110 |
Why?
|
| Neuroimaging | 1 | 2015 | 135 | 0.110 |
Why?
|
| Plasma Exchange | 1 | 2013 | 28 | 0.100 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2013 | 36 | 0.100 |
Why?
|
| Heart | 3 | 1990 | 591 | 0.100 |
Why?
|
| Cell Phone | 1 | 2013 | 39 | 0.100 |
Why?
|
| Aminoglycosides | 1 | 2013 | 32 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 1795 | 0.100 |
Why?
|
| Sexuality | 1 | 2013 | 42 | 0.100 |
Why?
|
| Communication | 1 | 2017 | 477 | 0.100 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2013 | 37 | 0.100 |
Why?
|
| Piperidines | 2 | 1985 | 171 | 0.100 |
Why?
|
| Radiography | 1 | 2015 | 813 | 0.100 |
Why?
|
| Heart Transplantation | 1 | 2019 | 812 | 0.100 |
Why?
|
| Awareness | 1 | 2013 | 90 | 0.100 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2013 | 52 | 0.100 |
Why?
|
| Vancomycin | 1 | 2013 | 74 | 0.100 |
Why?
|
| Immunologic Memory | 1 | 2014 | 188 | 0.100 |
Why?
|
| Minerals | 1 | 2012 | 21 | 0.100 |
Why?
|
| Triglycerides | 2 | 1992 | 236 | 0.100 |
Why?
|
| Isoantibodies | 1 | 2013 | 125 | 0.100 |
Why?
|
| Bone Density | 2 | 2004 | 236 | 0.100 |
Why?
|
| Cholesterol, HDL | 2 | 1992 | 173 | 0.100 |
Why?
|
| HLA Antigens | 1 | 2013 | 231 | 0.090 |
Why?
|
| Cesarean Section | 1 | 2013 | 157 | 0.090 |
Why?
|
| Nursing Staff, Hospital | 1 | 2012 | 46 | 0.090 |
Why?
|
| Reoperation | 5 | 2011 | 679 | 0.090 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 636 | 0.090 |
Why?
|
| Transplantation, Heterologous | 4 | 2021 | 377 | 0.090 |
Why?
|
| Blood | 2 | 2006 | 69 | 0.090 |
Why?
|
| Cholesterol | 2 | 1992 | 370 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1805 | 0.090 |
Why?
|
| Fertilization | 1 | 2011 | 41 | 0.090 |
Why?
|
| Immunization Schedule | 1 | 2010 | 23 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 381 | 0.080 |
Why?
|
| Cohort Studies | 4 | 2021 | 3093 | 0.080 |
Why?
|
| Ethics, Medical | 3 | 2008 | 312 | 0.080 |
Why?
|
| Nicardipine | 1 | 1990 | 7 | 0.080 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 3901 | 0.080 |
Why?
|
| Young Adult | 7 | 2017 | 7001 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2012 | 900 | 0.080 |
Why?
|
| Prevalence | 2 | 2008 | 1345 | 0.080 |
Why?
|
| Infertility, Female | 1 | 2010 | 101 | 0.080 |
Why?
|
| Hematuria | 1 | 2009 | 50 | 0.080 |
Why?
|
| Virus Replication | 2 | 2011 | 326 | 0.070 |
Why?
|
| CD3 Complex | 3 | 2012 | 136 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 457 | 0.070 |
Why?
|
| Muromonab-CD3 | 4 | 1997 | 70 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2010 | 244 | 0.070 |
Why?
|
| Rabbits | 2 | 2006 | 649 | 0.070 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2009 | 83 | 0.070 |
Why?
|
| Prognosis | 3 | 2019 | 4024 | 0.070 |
Why?
|
| Heart Ventricles | 4 | 1990 | 810 | 0.070 |
Why?
|
| Mycophenolic Acid | 2 | 1998 | 86 | 0.070 |
Why?
|
| Biomarkers | 2 | 2013 | 1933 | 0.070 |
Why?
|
| Siblings | 1 | 2008 | 109 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 850 | 0.070 |
Why?
|
| Acecainide | 1 | 1987 | 1 | 0.070 |
Why?
|
| Procainamide | 1 | 1987 | 4 | 0.070 |
Why?
|
| Age Factors | 3 | 2019 | 1963 | 0.070 |
Why?
|
| Preconception Care | 1 | 2007 | 9 | 0.070 |
Why?
|
| Delayed Graft Function | 1 | 2006 | 16 | 0.060 |
Why?
|
| Erythropoietin | 1 | 2007 | 91 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2019 | 4663 | 0.060 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2006 | 21 | 0.060 |
Why?
|
| Contraceptives, Oral | 1 | 2006 | 49 | 0.060 |
Why?
|
| Animals | 9 | 2021 | 28924 | 0.060 |
Why?
|
| Cross-Sectional Studies | 4 | 2015 | 1875 | 0.060 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2006 | 78 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2006 | 84 | 0.060 |
Why?
|
| Quinolones | 1 | 2006 | 58 | 0.060 |
Why?
|
| Prenatal Care | 1 | 2006 | 84 | 0.060 |
Why?
|
| Urine | 1 | 2006 | 96 | 0.060 |
Why?
|
| Chicago | 3 | 2018 | 1504 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 1028 | 0.060 |
Why?
|
| Immune System | 1 | 2006 | 103 | 0.060 |
Why?
|
| Fetus | 1 | 2006 | 239 | 0.060 |
Why?
|
| Costs and Cost Analysis | 3 | 2021 | 156 | 0.060 |
Why?
|
| Incidence | 1 | 2009 | 1705 | 0.060 |
Why?
|
| Radius | 1 | 2004 | 31 | 0.060 |
Why?
|
| Femur Neck | 1 | 2004 | 44 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2007 | 306 | 0.050 |
Why?
|
| Absorptiometry, Photon | 1 | 2004 | 109 | 0.050 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1984 | 69 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2024 | 1794 | 0.050 |
Why?
|
| Qualitative Research | 2 | 2015 | 362 | 0.050 |
Why?
|
| Registries | 2 | 2018 | 986 | 0.050 |
Why?
|
| Organophosphorus Compounds | 1 | 2003 | 53 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2003 | 155 | 0.050 |
Why?
|
| Recurrence | 5 | 2003 | 1216 | 0.050 |
Why?
|
| Thallium | 1 | 1982 | 8 | 0.050 |
Why?
|
| Dipyridamole | 1 | 1982 | 14 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 944 | 0.050 |
Why?
|
| Verapamil | 1 | 1982 | 34 | 0.050 |
Why?
|
| Propranolol | 1 | 1982 | 44 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 639 | 0.050 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2021 | 9 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 19 | 0.050 |
Why?
|
| Immunoglobulin G | 2 | 2021 | 481 | 0.050 |
Why?
|
| Lumbar Vertebrae | 1 | 2004 | 300 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2024 | 1969 | 0.040 |
Why?
|
| Palatine Tonsil | 1 | 2021 | 32 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2021 | 37 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1982 | 111 | 0.040 |
Why?
|
| Prostatectomy | 1 | 2024 | 480 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2022 | 192 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1007 | 0.040 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2000 | 4 | 0.040 |
Why?
|
| Decision Making | 2 | 2018 | 695 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2006 | 2943 | 0.040 |
Why?
|
| Physicians | 1 | 2008 | 711 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2021 | 173 | 0.040 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2001 | 109 | 0.040 |
Why?
|
| Healthcare Disparities | 2 | 2017 | 489 | 0.040 |
Why?
|
| Granuloma | 1 | 2000 | 65 | 0.040 |
Why?
|
| California | 1 | 2000 | 161 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2021 | 209 | 0.040 |
Why?
|
| Medical Records | 1 | 2000 | 124 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2021 | 281 | 0.040 |
Why?
|
| Regional Medical Programs | 1 | 2019 | 5 | 0.040 |
Why?
|
| Data Collection | 2 | 2014 | 382 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1173 | 0.040 |
Why?
|
| Radionuclide Imaging | 4 | 1985 | 217 | 0.040 |
Why?
|
| Public Sector | 1 | 2019 | 13 | 0.040 |
Why?
|
| Sweden | 1 | 2019 | 46 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2000 | 118 | 0.040 |
Why?
|
| Vaccination | 1 | 2021 | 311 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 84 | 0.040 |
Why?
|
| Risk Assessment | 4 | 2015 | 2478 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 205 | 0.040 |
Why?
|
| Social Participation | 1 | 2019 | 16 | 0.040 |
Why?
|
| Stakeholder Participation | 1 | 2018 | 24 | 0.040 |
Why?
|
| Stroke Volume | 4 | 1987 | 531 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 1990 | 111 | 0.040 |
Why?
|
| Fear | 1 | 2018 | 87 | 0.040 |
Why?
|
| Renal Replacement Therapy | 1 | 2018 | 43 | 0.030 |
Why?
|
| APACHE | 1 | 1998 | 24 | 0.030 |
Why?
|
| Brazil | 1 | 1998 | 82 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1998 | 274 | 0.030 |
Why?
|
| Drainage | 2 | 1998 | 170 | 0.030 |
Why?
|
| Research Report | 1 | 2018 | 43 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 125 | 0.030 |
Why?
|
| Duodenum | 1 | 1998 | 112 | 0.030 |
Why?
|
| Therapeutic Human Experimentation | 1 | 1997 | 20 | 0.030 |
Why?
|
| Portal Vein | 1 | 1998 | 122 | 0.030 |
Why?
|
| Urban Population | 1 | 2018 | 240 | 0.030 |
Why?
|
| Body Weight | 1 | 1998 | 460 | 0.030 |
Why?
|
| Survival Rate | 2 | 1998 | 1978 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 880 | 0.030 |
Why?
|
| Insurance, Health | 1 | 1998 | 180 | 0.030 |
Why?
|
| Heart Rate | 3 | 1985 | 519 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 1999 | 1618 | 0.030 |
Why?
|
| Actins | 1 | 1999 | 473 | 0.030 |
Why?
|
| Lipoprotein(a) | 2 | 1993 | 30 | 0.030 |
Why?
|
| Rats, Inbred Lew | 2 | 1994 | 210 | 0.030 |
Why?
|
| Mice | 4 | 2021 | 12559 | 0.030 |
Why?
|
| Cardiac Catheterization | 3 | 1987 | 330 | 0.030 |
Why?
|
| Poverty | 1 | 2017 | 196 | 0.030 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 1995 | 16 | 0.030 |
Why?
|
| Skin Transplantation | 2 | 1994 | 194 | 0.030 |
Why?
|
| Australia | 1 | 2015 | 124 | 0.030 |
Why?
|
| Crime | 1 | 2015 | 38 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 111 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 1998 | 481 | 0.030 |
Why?
|
| Flecainide | 2 | 1985 | 7 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 7205 | 0.030 |
Why?
|
| Conflict of Interest | 1 | 2015 | 77 | 0.030 |
Why?
|
| Victoria | 1 | 2014 | 5 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2017 | 415 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 189 | 0.030 |
Why?
|
| Health Services Research | 1 | 2015 | 147 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2015 | 122 | 0.030 |
Why?
|
| Neutralization Tests | 1 | 2014 | 77 | 0.030 |
Why?
|
| Pneumonia | 1 | 2016 | 198 | 0.030 |
Why?
|
| Videodisc Recording | 1 | 2013 | 2 | 0.030 |
Why?
|
| Software | 1 | 2018 | 699 | 0.030 |
Why?
|
| Morphine | 1 | 1995 | 130 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2016 | 246 | 0.030 |
Why?
|
| Perception | 1 | 2015 | 185 | 0.030 |
Why?
|
| Exercise Test | 3 | 1988 | 178 | 0.030 |
Why?
|
| Electronic Mail | 1 | 2013 | 17 | 0.030 |
Why?
|
| Liver | 1 | 2018 | 1237 | 0.030 |
Why?
|
| Midwestern United States | 1 | 2013 | 91 | 0.030 |
Why?
|
| Catheterization | 1 | 1995 | 238 | 0.030 |
Why?
|
| Text Messaging | 1 | 2013 | 35 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 1567 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 1006 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 178 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 2059 | 0.020 |
Why?
|
| Antigens, CD20 | 1 | 2012 | 35 | 0.020 |
Why?
|
| Diabetic Nephropathies | 1 | 1993 | 90 | 0.020 |
Why?
|
| Syndecan-1 | 1 | 2012 | 18 | 0.020 |
Why?
|
| Iran | 1 | 2012 | 17 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 599 | 0.020 |
Why?
|
| Electrophysiology | 2 | 1990 | 407 | 0.020 |
Why?
|
| Blood Glucose | 2 | 1996 | 873 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2014 | 348 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2016 | 644 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 2003 | 300 | 0.020 |
Why?
|
| Prednisone | 3 | 1997 | 259 | 0.020 |
Why?
|
| Emotions | 1 | 2015 | 377 | 0.020 |
Why?
|
| Electrocardiography | 3 | 1982 | 522 | 0.020 |
Why?
|
| Plasma Substitutes | 1 | 1991 | 10 | 0.020 |
Why?
|
| Atropine | 1 | 1991 | 61 | 0.020 |
Why?
|
| Workload | 1 | 2012 | 132 | 0.020 |
Why?
|
| Vagus Nerve | 1 | 1991 | 50 | 0.020 |
Why?
|
| Cardiac Tamponade | 1 | 1991 | 23 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 880 | 0.020 |
Why?
|
| Cytokines | 1 | 1995 | 873 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 1991 | 112 | 0.020 |
Why?
|
| Aortic Rupture | 1 | 1991 | 58 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 1991 | 92 | 0.020 |
Why?
|
| Lipoproteins | 1 | 1991 | 138 | 0.020 |
Why?
|
| Chemistry | 1 | 1990 | 54 | 0.020 |
Why?
|
| Cardiac Output, Low | 1 | 1990 | 14 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1990 | 72 | 0.020 |
Why?
|
| Kidney Glomerulus | 2 | 2003 | 122 | 0.020 |
Why?
|
| Rats | 2 | 1994 | 4134 | 0.020 |
Why?
|
| Amiodarone | 1 | 1989 | 15 | 0.020 |
Why?
|
| Angina Pectoris | 1 | 1988 | 29 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 1995 | 2092 | 0.020 |
Why?
|
| Reference Values | 1 | 1990 | 674 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 1994 | 3489 | 0.020 |
Why?
|
| Myocardial Contraction | 2 | 1987 | 253 | 0.020 |
Why?
|
| Propanolamines | 1 | 1988 | 18 | 0.020 |
Why?
|
| Fluorobenzenes | 1 | 1988 | 34 | 0.020 |
Why?
|
| Bioethics | 1 | 2008 | 37 | 0.020 |
Why?
|
| Aortography | 1 | 1987 | 67 | 0.020 |
Why?
|
| Polycythemia | 1 | 2007 | 8 | 0.020 |
Why?
|
| Portugal | 1 | 2007 | 26 | 0.020 |
Why?
|
| Depression, Chemical | 1 | 1987 | 27 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1981 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1988 | 200 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 1988 | 273 | 0.020 |
Why?
|
| Ventricular Function | 1 | 1987 | 55 | 0.020 |
Why?
|
| Aortic Valve Insufficiency | 1 | 1987 | 143 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 1990 | 428 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 1985 | 51 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 1985 | 104 | 0.010 |
Why?
|
| Echocardiography | 2 | 1987 | 1004 | 0.010 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1985 | 123 | 0.010 |
Why?
|
| Fibrosis | 1 | 2005 | 246 | 0.010 |
Why?
|
| Tachycardia | 1 | 1984 | 36 | 0.010 |
Why?
|
| Pilot Projects | 2 | 1997 | 936 | 0.010 |
Why?
|
| Heart Aneurysm | 1 | 1983 | 22 | 0.010 |
Why?
|
| Electroencephalography | 1 | 1988 | 824 | 0.010 |
Why?
|
| Integrin beta3 | 1 | 2003 | 32 | 0.010 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2003 | 36 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2003 | 163 | 0.010 |
Why?
|
| Kidney Tubules | 1 | 2003 | 93 | 0.010 |
Why?
|
| Physical Exertion | 1 | 1982 | 39 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1984 | 1010 | 0.010 |
Why?
|
| Radioisotopes | 1 | 1982 | 43 | 0.010 |
Why?
|
| Viral Load | 1 | 2003 | 165 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2003 | 339 | 0.010 |
Why?
|
| Risk-Taking | 1 | 2002 | 163 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 437 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2002 | 232 | 0.010 |
Why?
|
| Cell Count | 1 | 2001 | 203 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2001 | 111 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2001 | 313 | 0.010 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2001 | 59 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 2001 | 126 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2001 | 179 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2001 | 311 | 0.010 |
Why?
|
| Arterioles | 1 | 1999 | 29 | 0.010 |
Why?
|
| Aging | 1 | 2003 | 766 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1999 | 380 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1999 | 243 | 0.010 |
Why?
|
| Biological Availability | 1 | 1998 | 90 | 0.010 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 1997 | 10 | 0.010 |
Why?
|
| Complement C3 | 1 | 1997 | 58 | 0.010 |
Why?
|
| Blood Group Incompatibility | 1 | 1997 | 22 | 0.010 |
Why?
|
| Urinary Retention | 1 | 1997 | 46 | 0.010 |
Why?
|
| Peer Review, Research | 1 | 1997 | 37 | 0.010 |
Why?
|
| Fibrin | 1 | 1997 | 87 | 0.010 |
Why?
|
| ABO Blood-Group System | 1 | 1997 | 60 | 0.010 |
Why?
|
| Confidentiality | 1 | 1997 | 80 | 0.010 |
Why?
|
| Child | 1 | 2008 | 7624 | 0.010 |
Why?
|
| Cineangiography | 2 | 1987 | 13 | 0.010 |
Why?
|
| Neutrophils | 1 | 1997 | 334 | 0.010 |
Why?
|
| Antibodies | 1 | 1997 | 356 | 0.010 |
Why?
|
| Interleukin-5 | 1 | 1995 | 36 | 0.010 |
Why?
|
| Monitoring, Immunologic | 1 | 1995 | 19 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 1997 | 372 | 0.010 |
Why?
|
| DNA | 1 | 2001 | 1332 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1996 | 872 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1997 | 359 | 0.010 |
Why?
|
| Informed Consent | 1 | 1997 | 281 | 0.010 |
Why?
|
| Rats, Inbred ACI | 1 | 1994 | 25 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1994 | 73 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 1994 | 40 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 1995 | 166 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1996 | 1536 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1995 | 489 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1993 | 279 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 713 | 0.010 |
Why?
|
| Isotonic Solutions | 1 | 1991 | 18 | 0.010 |
Why?
|
| Plasminogen | 1 | 1991 | 47 | 0.010 |
Why?
|
| Angiography | 1 | 1988 | 209 | 0.000 |
Why?
|
| Angiocardiography | 1 | 1987 | 31 | 0.000 |
Why?
|
| History, 20th Century | 1 | 1989 | 326 | 0.000 |
Why?
|
| Fistula | 1 | 1983 | 42 | 0.000 |
Why?
|
| Rest | 1 | 1982 | 53 | 0.000 |
Why?
|
| Coronary Angiography | 1 | 1983 | 261 | 0.000 |
Why?
|